Zymeworks Early R&D Day Highlights Progress in Development of Novel Pipeline Assets and Applications of Proprietary Next-Generation Technology Platforms
October 20 2022 - 8:30AM
Business Wire
- Program beginning today at 8:30 AM Eastern Standard Time (EST)
to feature updates and perspectives from Zymeworks senior
leadership and scientific experts
- Progress in early-stage research designed to support Company
goal to file up to five new Investigational New Drug (IND)
applications in the next five years
- Live webcast to be available on the Investors & Media
section of Zymeworks’ website at www.zymeworks.com
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a
clinical-stage biopharmaceutical company developing multifunctional
biotherapeutics, today announced the highlights from its early
R&D Day reviewing the Company’s progress and plans for the
development of its novel pipeline assets and applications of its
proprietary next-generation technology platforms.
“This event is an important opportunity for us to provide an
update on our progress in developing the next generation of
innovative therapeutics based on our proprietary engineering
platforms and integrated technologies,” said Kenneth Galbraith,
Chair and CEO of Zymeworks. “During the program we will review
recent data related to our antibody drug conjugates (ADC) and
multi-specific antibody therapeutics (MSAT). Our goal at Zymeworks
is to submit five Investigational Drug Applications in the next
five years, and we believe today’s early R&D Day will
demonstrate that we have the momentum, expertise, and resources in
place to be successful in developing the next wave of potential
best-in-class therapeutics.”
The event will include presentations on ADC and MSAT research
programs and emerging pipeline candidates that expand the Company’s
focus on cancer indications with significant unmet patient needs.
Similarly, the event will highlight the future development path and
strategy that we believe will help drive the next advances in
antibody-based therapeutics.
Presenters will include:
- Paul Moore, Ph.D., Chief Scientific Officer
- Stuart Barnscher, Director, Preclinical Programs, ADC
Therapeutics Development
- Jamie Rich, Ph.D., Director, Technology, ADC Therapeutic
Development
- Thomas Spreter Von Kreudenstein, Ph.D., Director, Protein
Engineering
- Nina Weisser, Ph.D., Director, Multispecific Antibody
Therapeutics
“Our team is excited to have the opportunity to share these
important updates and provide insight into the future in
antibody-based therapeutics we are pursuing at Zymeworks,” said
Paul Moore, Ph.D., Chief Scientific Officer of Zymeworks. “The use
of our advanced technology platforms and continued scientific
advancements in both protein engineering and antibody conjugation
brings us further towards our goal of addressing difficult to treat
cancers with traditionally poor patient prognosis.”
Zymeworks Early R&D Day Program Highlights
Update on the Company’s ADC programs, including:
- Topoisomerase 1 inhibitor (TOPO1i) payload
- ZW191– a Folate Receptor-alpha targeted topoisomerase-1
ADC
- ZW251 – a Glypican-3 targeted topoisomerase-1 ADC
- ZW220 – a NaPi2b targeted topoisomerase-1 ADC
Review of progress in MSAT development, including:
- ZW171– a Mesothelin x CD3 targeted 2+1 format bispecific
antibody
- Tri-specific T-cell Engagers incorporating co-stimulation
(TriTCE-costim)
- Tri-specific T-cell Engagers incorporating checkpoint
inhibition (TriTCE-CPI)
Early R&D Day Webcast Information
A live webcast of the Company’s Early R&D Day event will be
available on the Investors & Media section of Zymeworks’
website, www.zymeworks.com. A replay of the webcast will be
available following the presentation.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
next-generation multifunctional biotherapeutics. Zymeworks’ suite
of therapeutic platforms and its fully integrated drug development
engine enable precise engineering of highly differentiated product
candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a
novel Azymetric™ HER2-targeted bispecific antibody currently being
evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials
globally as a targeted treatment option for patients with solid
tumors that express HER2. Zymeworks’ second clinical candidate,
zanidatamab zovodotin (ZW49), is a novel bispecific HER2 ‑targeted
antibody-drug conjugate currently in Phase 1 clinical development
and combines the unique design and antibody framework of
zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and
cytotoxin. Zymeworks is also advancing a deep preclinical pipeline
in oncology (including immuno-oncology agents) and other
therapeutic areas. In addition, its therapeutic platforms are being
leveraged through strategic partnerships with global
biopharmaceutical companies. For more information on our ongoing
clinical trials visit www.zymeworksclinicaltrials.com. For
additional information about Zymeworks, visit www.zymeworks.com and
follow @ZymeworksInc on Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or
information within the meaning of the applicable securities
legislation, including Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Forward-looking statements in this press release
include, but are not limited to, statements that relate to
Zymeworks’ preclinical pipeline, Zymeworks’ development of
potential product candidates, expectations regarding future
regulatory filings and the timing thereof, the commercial potential
of technology platforms and product candidates, Zymeworks’ ability
to identify additional development candidates and successfully
advance such candidates through clinical development, Zymeworks’
ability to develop best-in-class therapeutics and other information
that is not historical information. When used herein, words such as
“plan”, “hope”, “believe”, “expect”, “may”, “continue”,
“anticipate”, “potential”, “will”, “progress”, “look forward”, and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
Zymeworks’ current expectations and various assumptions. Zymeworks
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. Zymeworks may not
realize its expectations, and its beliefs may not prove correct.
Actual results could differ materially from those described or
implied by such forward-looking statements as a result of various
factors, including, without limitation: preclinical studies may not
support continued development of potential product candidates;
future clinical trials may not demonstrate safety and efficacy of
any of Zymeworks’ or its collaborators’ product candidates; any of
Zymeworks’ or its partners’ product candidates may fail in
development, may not receive required regulatory approvals, or may
be delayed to a point where they are not commercially viable;
regulatory agencies may impose additional requirements or delay the
initiation of clinical trials; the impact of the COVID-19 pandemic
on Zymeworks’ business, research and clinical development plans and
timelines and results of operations, including impact on its
clinical trial sites, collaborators, and contractors who act for or
on Zymeworks’ behalf, may be more severe and more prolonged than
currently anticipated; the impact of new or changing laws and
regulations; market conditions; Zymeworks’ assumptions regarding
its financial condition, future cash needs or future financial
performance may be incorrect; inability to maintain or enter into
new partnerships or strategic collaborations; and the factors
described under “Risk Factors” in Zymeworks’ quarterly and annual
reports filed with the Securities and Exchange Commission,
including the Quarterly Report on Form 10-Q filed by Zymeworks BC
Inc. for its quarter ended June 30, 2022 (a copy of which may be
obtained at www.sec.gov and www.sedar.com).
Although Zymeworks believes that such forward-looking statements
are reasonable, there can be no assurance they will prove to be
correct. Investors should not place undue reliance on
forward-looking statements. The above assumptions, risks and
uncertainties are not exhaustive. Forward-looking statements are
made as of the date hereof and, except as may be required by law,
Zymeworks undertakes no obligation to update, republish, or revise
any forward-looking statements to reflect new information, future
events or circumstances, or to reflect the occurrences of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221020005335/en/
Investor inquiries: Jack Spinks (604) 678-1388
ir@zymeworks.com Media inquiries: Diana Papove (604)
678-1388 media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Jul 2023 to Jul 2024